Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oculomucocutaneous syndrome23.03.01.022; 07.05.01.010; 06.04.05.0140.000585%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema mouth10.01.05.006; 07.05.04.001; 23.04.01.0080.001169%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.001169%
Oliguria20.01.03.0040.000585%Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.0030.000877%
Paraesthesia17.02.06.005--
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.001169%Not Available
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Platelet count decreased13.01.04.0010.001462%
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Protein total decreased13.09.01.0040.000585%Not Available
Prothrombin time prolonged13.01.02.0120.000877%Not Available
Prothrombin time ratio decreased13.01.02.0400.000585%Not Available
Pruritus23.03.12.0010.002631%
Pulmonary alveolar haemorrhage22.01.02.005; 24.07.01.0150.000585%Not Available
Purpura01.01.04.003; 24.07.06.005; 23.06.01.0040.001462%
Pyrexia08.05.02.0030.003800%
Rash23.03.13.001--Not Available
Rash generalised23.03.13.0020.000877%Not Available
Restlessness19.11.02.002; 17.02.05.0210.001169%
Rhinorrhoea22.02.05.0100.000585%
Sedation17.02.04.0050.000877%Not Available
Seizure17.12.03.0010.002046%
Shock24.06.02.002--Not Available
Sinus congestion22.04.06.0010.000585%Not Available
Skin exfoliation23.03.07.0030.000585%Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages